Capital Support
A financing process of up to a total of 180 million TL has started for the projects selected by our scientific committees, which are suitable for the foundation purpose of the fund.
Intellectual Property Rights
All Intellectual and Industrial Property Rights arising from the project will belong to the companies to be established in partnership with the inventors and the Fund.
Trustlife Labs Drug R&D Center
The laboratories within the Trustlife Labs Drug R&D Center affiliated with GSYF have the necessary technical equipment and human resources for R&D activities.
Financial Returns
When the project is completed, it will be ensured that the company reaches an important economic value and our scientists will also benefit from this value.
Key Stages of Our Cooperation
1.
Prioritization
Lead researchers with product development potential are identified.
2.
Invitation
Project proposals are received by invitation and/or open call method.
3.
Online Conversations
An online pre-interview is held before the project presentation to the invited scientists or organizations.
4.
Project Application
Documents that require a wet signature for the completion of the project application are delivered to the Fund management center.
5.
Scientific Evaluation Process
Projects are evaluated by impartial panelist teams formed by the Trustlife Science Board.
6.
Financial Evaluation Process
It is done by experts and institutions selected by the Trustlife Advisory Board.
7.
Incorporation
It aims to complete the entire legal process, including establishing a company for projects with high scores. The final results are given by the GSYF Investment Committee.
8.
Budget Transfer
The expenditure plan of the project is created by considering the stages of the project. The investment is initiated with the approval of the GSYF Investment Committee.
Trustlife Labs Drug R&D Center
DETAILSIt has the modern technological infrastructure necessary for the complete realization of 'Drug Design' and 'Pre-Clinical Studies' in the drug development process. It serves the fund intending to develop and commercialize original drugs.
- Design of new bioactive molecules using computer-aided modeling techniques
- Modeling of small organic molecules, proteins, and protein-ligand interactions
- Ligand-based and structure-based pharmacophore design
- Creation and scanning of large virtual combinatorial composite libraries
- Molecular activity determination using 3D-QSAR
- 27 Med-Chem Synthesis Stations
Development of synthetic strategies to make small molecules as precursor compounds, drug design, and discovery - Full Characterization
Multistage organic synthesis, development, purification, and characterization of homogeneous and heterogeneous organic compounds
- 4 Cell Line Stations
- Activity evaluation
- Toxicity screening
- Genotoxicity assessment Modeling
- Biocompatibility tests
- In vitro disease models
- Dissolution and Permeability improvement strategies
- New generation drug delivery systems
- Smart microfluidics adaptation
- Nanotechnology applications
- Lab-on-chip systems, Organ-on-a-chip
- High-pressure homogenization
- Liposomes, SLNs
- Open/Closed Cycle Spray Drying
Innovative Drug Development Process
The Trustlife methodology shortens the time of finding biomarkers and drug targets and manages the pre-clinical stages from a single center by generating multi-omic data, using systems biology and artificial intelligence approaches. Trustlife methodology aims to reduce drug development time from 14-15 years to 6-7 years.
1.
TargetingIn addition to producing multi-omic data for detailed characterization of healthy subjects and patients with different diseases, it is aimed to identify genes and proteins that can be used as therapeutic targets by using extensive bioinformatics resources.
2.
Drug Design and Pre-Clinical StudiesThe continuation of theoretical in silico studies for target validation and candidate drug development is all basic research including chemical synthesis, formulation, cell, and animal studies.
3.
Clinical StudiesDesigns Phase I, Phase II, and Phase III processes that include safety, pharmacokinetics, dose determination, and efficacy studies.
4.
CommercializationWith the approach of establishing a joint company, when the project is completed, it will be ensured that the company reaches an important economic value and that our scientists will also benefit from this value, and that their efforts will be rewarded.
Projects by Trustlife Labs Serviced
Pancreatic Cancer
Pancreatic cancer occurs when cells in the pancreas, a glandular organ at the back of the stomach, grow out of control and form a mass. The most common pancreatic adenocarcinoma accounts for about 90% of cases, and the term "pancreatic cancer" is sometimes used to refer to just this type. Our aim in this project is to develop new compounds as active ingredients for the treatment of pancreatic cancer.
GBM (Glioblastoma)
Glioblastoma multiform (GBM) is an aggressive type of cancer that can occur in the brain or spinal cord. It can cause worsening headaches, nausea, vomiting, and seizures. Our research team has identified specific gene targets related to Glioblastoma. Our strategy is to develop new compounds as active ingredients for the treatment of GBM disease.
Sarcopenia
(Aging-related muscle wasting)Sarcopenia, or the reduction of skeletal muscle tissue with age, is one of the most important causes of functional decline and loss of independence in older adults. Mechanisms controlling muscle mass have received increasing attention because various clinical conditions are associated with muscle mass reduction, including aging and many diseases such as diabetes, lung diseases, and cancer cachexia. Our aim in this study is to develop new compounds as medicinal agents for the treatment of Sarcopenia disease.
Kidney Cancer
Clear cell renal cell carcinoma or ccRCC is a type of kidney cancer. Renal cell carcinoma (RCC) is the most common type of kidney cancer found in adults. It constitutes 2-6% of childhood and young adult kidney cancer cases. Our research team has identified specific gene targets related to kidney cancer. We aim to develop medicinal compounds for the treatment of kidney cancer.
Liver Cancer
Non-alcoholic fatty liver disease (NAFLD) is the term used for several conditions caused by the accumulation of fat in the liver. It affects 25% of the global adult population (those with type 2 diabetes or metabolic syndrome) and is the most common chronic liver disease worldwide. To this end, our research team identified PCL as a target protein in the liver. Our study aim is to develop compounds as medicinal agents, and synthesizepotent small molecule Activators and Inhibitors for the treatment of fatty liver diseases by targeting the PCL protein.
Prostate Cancer
Prostate cancer (PC) is considered one of the most incurable and aggressive pathologies despite high-level research, with a mortality rate of 2% in men diagnosed. Preliminary studies have already been completed by our bioinformatics center to identify active genes and specific drugs targeted for the treatment of PK. Within the scope of the project, it is aimed to synthesize new and unique drug molecules and complete preclinical studies.
Our Collaborations
